Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

被引：449

作者：

Crews, K. R. ^{[1
]}

Gaedigk, A. ^{[2
,3
]}

Dunnenberger, H. M. ^{[1
]}

Leeder, J. S. ^{[2
,3
]}

Klein, T. E. ^{[4
]}

Caudle, K. E. ^{[1
]}

Haidar, C. E. ^{[1
]}

Shen, D. D. ^{[5
,6
]}

Callaghan, J. T. ^{[7
,8
]}

Sadhasivam, S. ^{[9
,10
]}

Prows, C. A. ^{[11
,12
]}

Kharasch, E. D. ^{[13
]}

Skaar, T. C. ^{[7
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Childrens Mercy Hosp & Clin, Div Clin Pharmacol & Therapeut Innovat, Kansas City, MO USA

[3] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[4] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[5] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA

[6] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA

[7] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA

[8] RLR VA Med Ctr, Dept Vet Affairs, Indianapolis, IN USA

[9] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA

[10] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA

[11] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA

[12] Cincinnati Childrens Hosp Med Ctr, Div Patient Serv, Cincinnati, OH 45229 USA

[13] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 04期

基金：

美国医疗保健研究与质量局;

关键词：

CYP2D6 ACTIVITY SCORE; BREAST-FED NEONATE; ULTRARAPID-METABOLISM; MORPHINE FORMATION; CANCER-PATIENTS; OXYCODONE; TRAMADOL; PHARMACOKINETICS; PHENOTYPE; PHARMACODYNAMICS;

D O I：

10.1038/clpt.2013.254

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

引用

页码：376 / 382

页数：7

共 50 条

[1] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Shen, D. D.
Callaghan, J. T.
Kharasch, E. D.
Skaar, T. C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 321 - 326
[2] Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy
Brown, Jacob T.
Bishop, Jeffrey R.
Sangkuhl, Katrin
Nurmi, Erika L.
Mueller, Daniel J.
Dinh, Jean C.
Gaedigk, Andrea
Klein, Teri E.
Caudle, Kelly E.
McCracken, James T.
de Leon, Jose
Leeder, J. Steven
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) : 94 - 102
[3] Cytochrome P450 2D6 and treatment of codeine dependence
Romach, MK
Otton, SV
Somer, G
Tyndale, RF
Sellers, EM
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (01) : 43 - 45
[4] Treatment of codeine dependence with inhibitors of cytochrome P450 2D6
Fernandes, LC
Kilicarslan, T
Kaplan, HL
Tyndale, RF
Sellers, EM
Romach, MK
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (03) : 326 - 329
[5] Cytochrome P450 2D6
Owen, Ryan P.
Sangkuhl, Katrin
Klein, Teri E.
Altman, Russ B.
PHARMACOGENETICS AND GENOMICS, 2009, 19 (07): : 559 - 562
[6] Clinical Perspective on the Clinical Pharmacogenetics Implementation Consortium Updated 2014 Guidelines for CYP2D6 and Codeine
Nicholson, Wayne T.
Formea, Christine M.
CLINICAL CHEMISTRY, 2015, 61 (02) : 319 - 321
[7] Cytochrome P450 2D6 based electrochemical sensor for the determination of codeine
Asturias-Arribas, Laura
Asuncion Alonso-Lomillo, M.
Dominguez-Renedo, Olga
Julia Arcos-Martinez, M.
TALANTA, 2014, 129 : 315 - 319
[8] Inhibition of cytochrome P450 2D6 modifies codeine abuse liability
Kathiramalainathan, K
Kaplan, HL
Romach, MK
Busto, UE
Li, NY
Säwe, J
Tyndale, RF
Sellers, EM
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (04) : 435 - 444
[9] Cytochrome P450 2D6 genotype variation and venlafaxine dosage
McAlpine, Donald E.
O'Kane, Dennis J.
Black, John L.
Mrazek, David A.
MAYO CLINIC PROCEEDINGS, 2007, 82 (09) : 1065 - 1068
[10] Allosteric effects of cytochrome P450 reductase on cytochrome P450 2D6
Roberts, GCK
Modi, S
Gilham, DE
Sutcliffe, MJ
Lian, LY
Primrose, WU
Wolf, CR
FASEB JOURNAL, 1997, 11 (09): : A789 - A789

← 1 2 3 4 5 →